WestPark Capital announces closing of Arrogene NanoTechnology offering
On February 8, 2012, WestPark Capital Inc. has made a second closing of a private placement for Arrogene NanoTechnology Inc.
A total of 610,000 units, each unit consisting of one share of common stock and two common stock purchase warrants, were sold, generating gross proceeds in excess of $600,000.
The second closing follows an initial closing of $500,000 on January 20, 2012.
Net proceeds from the offering will be used for working capital and research and development related to Arrogene’s diagnostic and therapeutic technologies for brain, breast and lung cancer.
WestPark Capital acted as placement agent for the offering.
Source: WestPark Capital
Related Posts
- Facebook prices IPO at $38 per share
- Altera closes $500M senior notes offering
- iStar Financial prices $275M senior notes offering
- iStar Financial to sell $275M of senior notes offering
- Zions Bancorporation completes $143.75M preferred stock auction
- Acquity Group prices IPO
- Western Asset Mortgage Capital launches IPO of 8 million common stock shares
- LyondellBasell prices $2B of senior notes
- New Gold to launch $300M senior notes offering
- Firm Capital Mortgage Investment closes bought deal financing
Tweet This
Share on Facebook
Digg This
Save to delicious
Stumble it
RSS Feed
